DHEA on Sexual Function in Sheehan Syndrome: A Randomized Double-Blind Placebo-Controlled Crossover Trial

Context The majority of women with Sheehan syndrome (SS) suffer from sexual dysfunction. Severe androgen deficiency is a major contributory factor. Dehydroepiandrosterone (DHEA) supplementation has been reported to have variable efficacious in improving female sexual dysfunction (FSD) in several trials but studies using DHEA in SS are not available. Objective We aimed to study the use of DHEA supplementation in patients with SS. Methods In this crossover trial, 28 participants with SS (age 39.7 +/- 8.6 years) were divided into 2 groups (using block randomization) who received DHEA supplements (25 mg twice daily) or matched placebo sequentially for 3 months each. Female Sexual Functioning Index (FSFI) score and serum DHEA sulfate (DHEAS) were measured at baseline and after completion of each phase. Glycemic parameters, lipid profile, and liver enzymes were also measured to assess metabolic side effects. Results There was significant improvement in FSFI score from baseline to end of the study in the DHEA group compared with the placebo group (P = 0.006). Mean FSFI score and most of the individual domains of female sexual dysfunction (FSD) improved with DHEA significantly in both groups (P = 0.001 for each group with DHEA). In those who received DHEA first followed by placebo, FSFI declined significantly after placebo (P = 0.041) but remained at an acceptable level of sexual functioning. Serum DHEAS increased significantly with DHEA treatment. No significant changes in glycemic index, lipid profile, and liver enzymes were noted with DHEA treatment. Conclusion A short duration of DHEA supplementation in women with SS with FSD is efficacious and safe.

Automated summary

This study aimed to investigate the use of DHEA supplementation in patients with Sheehan syndrome (SS). The results showed that DHEA supplementation significantly improved the Female Sexual Functioning Index (FSFI) score, with significant improvements in both FSFI score and individual domains of female sexual dysfunction (FSD). Furthermore, DHEA treatment did not result in any metabolic side effects.